SAN ANTONIO – Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better ...
At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and ...
You have a critical role in determining your breast cancer treatment plan. Here’s how you can work with your doctor. According to the National Cancer Institute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results